AI Article Synopsis
- The study aimed to assess if vaccinations worsen autoimmune diseases like juvenile idiopathic arthritis (JIA) and if immunosuppressive therapy affects vaccination response.
- 234 JIA patients (ages 1-19) were vaccinated with the MenC vaccine and monitored for disease activity for one year, showing no worsening of disease symptoms or relapse rates post-vaccination.
- The results indicated that the MenC vaccine is safe for JIA patients, as it didn't worsen their condition and effectively triggered a strong immune response, even in those on immunosuppressive treatments.
Article Abstract
Objective: To determine whether vaccinations aggravate the course of autoimmune diseases such as juvenile idiopathic arthritis (JIA) and whether the immune response to vaccinations may be hampered by immunosuppressive therapy for the underlying disease.
Methods: In this multicenter cohort study, 234 patients with JIA (ages 1-19 years) were vaccinated with meningococcal serogroup C (MenC) conjugate to protect against serogroup C disease (caused by Neisseria meningitidis). Patients were followed up for disease activity for 1 year, from 6 months before until 6 months after vaccination. IgG antibody titers against MenC polysaccharide and the tetanus carrier protein were determined by enzyme-linked immunosorbent assay and toxin binding inhibition assay, respectively. A serum bactericidal assay was performed to determine the function of the anti-MenC antibodies.
Results: No change in values for any of the 6 components of the core set criteria for juvenile arthritis disease activity was seen after MenC vaccination. Moreover, no increase in the frequency of disease relapse was detected. Mean anti-MenC IgG concentrations in JIA patients rose significantly within 6-12 weeks after vaccination. Of 157 patients tested, 153 were able to mount anti-MenC IgG serum levels >2 micro g/ml, including patients receiving highly immunosuppressive medication. The 4 patients with a lower anti-MenC antibody response displayed sufficient bactericidal activity despite receiving highly immunosuppressive medication.
Conclusion: The MenC conjugate vaccine does not aggravate JIA disease activity or increase relapse frequency and results in adequate antibody levels, even in patients receiving highly immunosuppressive medication. Therefore, patients with JIA can be vaccinated safely and effectively with the MenC conjugate.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/art.22399 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Global Epidemiology of Meningococcal Disease-Causing Serogroups Before and After the COVID-19 Pandemic: A Narrative Review.
Infect Dis Ther
December 2024
Pfizer Global Medical Affairs, Vaccines and Antivirals, Pfizer Inc, Collegeville, PA, USA.
Invasive meningococcal disease (IMD) is associated with high morbidity and mortality and predominantly caused by five Neisseria meningitidis serogroups (A/B/C/W/Y). Polysaccharide conjugate vaccines induce T-cell-dependent immune responses, are immunogenic in infants and adults, and reduce carriage, and vaccination of age groups associated with high-carriage can provide indirect protection in the unvaccinated (herd immunity). Successful vaccination programs must be tailored to local epidemiology, which varies geographically, temporally, and by age and serogroup.
View Article and Find Full Text PDFEstimating the potential number of cases prevented by infant/ toddler immunisation with a MenACWY vaccine.
Vaccine
October 2024
Disease Dynamics Unit, University of Cambridge, United Kingdom.
Article Synopsis
- - The UK is reassessing its meningococcal disease vaccination strategy due to the discontinuation of the Menitorix® vaccine, with the MenACWY vaccine being considered a key solution integrated into teenage immunizations, while infant vaccination remains important due to high incidence rates.
- - Two UK studies were analyzed to adjust age-specific meningococcal carriage data, utilizing a dynamic model to assess the effects of MenACWY vaccinations for teenagers and infants, also factoring in changes during COVID-19 lockdowns.
- - Projections suggest the teenage MenACWY vaccination will effectively reduce disease carriage to below 1% by 2025, while infant vaccination at 3 months is more effective in preventing cases than at 12 months
Effectiveness and duration of protection of primary and booster immunisation against meningococcal serogroup C disease with meningococcal conjugate C and ACWY vaccines: Systematic review.
J Infect
September 2024
Robert Koch Institute, Immunisation Unit, Seestrasse 10, 13353 Berlin, Germany. Electronic address:
Objectives: To estimate vaccine effectiveness (VE) and duration of protection of single primary and booster immunisation with meningococcal C (MenC) and ACWY (MenACWY) conjugate vaccines in preventing MenC invasive meningococcal disease (IMD).
Methods: We performed a systematic review on studies of VE and immunogenicity (rSBA/hSBA titers) of participants aged 12-23 months for primary and 6-18 years for booster immunisation (last search: 18 August 2023). Risk of bias and certainty of evidence were evaluated (PROSPERO: CRD42020178773).
Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix in Healthy Adolescents: A Randomized Phase IIIb Multicenter Study.
Infect Dis Ther
August 2024
Isabelle Betrand-Gerentes, Global Medical, Sanofi Vaccines, 14 Espa. Henry Vallée, 69007, Lyon, France.
Introduction: Many immunization programs in Europe recommend quadrivalent meningococcal vaccinations, which are often administered concomitantly with other vaccines. We compared the immune response of a tetanus toxoid conjugated quadrivalent meningococcal vaccine (MenACYW-TT, MenQuadfi) with another quadrivalent meningococcal conjugate vaccine (MCV4-TT; Nimenrix) when administered alone or concomitantly with Tdap-IPV and 9vHPV vaccines in adolescents.
Methods: In this phase IIIb trial, healthy adolescents (MenC-naïve or MenC-primed before 2 years of age) from Spain, Italy, Hungary, and Singapore were randomized in a 3:3:2 ratio to receive either MenACYW-TT or MCV4-TT alone, or MenACYW-TT concomitantly with 9vHPV and Tdap-IPV.
A Fluorinated Sialic Acid Vaccine Lead Against Meningitis B and C.
J Am Chem Soc
June 2024
Institute for Organic Chemistry, University of Münster, Corrensstraße 36, Münster 48149, Germany.
Inspired by the specificity of α-(2,9)-sialyl epitopes in bacterial capsular polysaccharides (CPS), a doubly fluorinated disaccharide has been validated as a vaccine lead against serogroups C and/or B. Emulating the importance of fluorine in drug discovery, this molecular editing approach serves a multitude of purposes, which range from controlling α-selective chemical sialylation to mitigating competing elimination. Conjugation of the disialoside with two carrier proteins (CRM197 and PorA) enabled a semisynthetic vaccine to be generated; this was then investigated in six groups of six mice.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!